NOTA! Questo sito utilizza i cookie e tecnologie simili.

Se non si modificano le impostazioni del browser, l'utente accetta. Per saperne di piu'

Approvo

iM3SH. International panel discussion on new scientific evidences and their impact on mCRC clinical practice

iM3SH. International panel discussion on new scientific evidences and their impact on mCRC clinical practice

Stresa, 12 aprile 2019

Direttori: Filippo G. De Braud, Alfredo Falcone, Alberto Sobrero.
The therapeutic choice for patients with mCRC is becoming harder because of the availability of four chemotherapic agents and five biological drugs. The therapeutic approach requires the definition of the strategy that must consider the tumor and the patients features. Following the decision on how to start treatment, we also need to consider that the choice includes various other factors: how to continue first-line treatment after induction therapy, how to carry on maintenance therapy, when it is possible to talk about second-line, biological drugs: which one and when, metastasis resection: when. All these key issues have been discussed by an Internationally renowned panel.
Per accedere alle diapositive del convegno è necessario essere registrati al portale ASKIT. Se sei già registrato Accedi e inserisci il tuo Nome utente e la tua password. Se è la prima volta che accedi ad ASKit, registrati adesso.
 

Relazioni